Travere Therapeutics, Inc. has announced the appointment of Bradley L. Campbell as its new President and Chief Executive Officer, effective December 1, 2026. Campbell will also join the company's Board of Directors immediately upon taking office. He succeeds Eric Dube, Ph.D., who will step down from his role as CEO and Board member on the same date.
Under the terms of a Transition and Separation Agreement, Dr. Dube will remain with the company through February 15, 2027, to assist with the leadership transition. During this period, he will serve as an Executive Advisor and Consultant to Campbell. Dr. Dube will continue to receive his current base salary and is eligible for his 2026 cash incentive bonus, though he will not receive a bonus for 2027. Additionally, the company has agreed to pay for Dr. Dube's COBRA health insurance premiums for up to 18 months following his resignation.
Bradley Campbell brings over 25 years of biopharmaceutical experience, having previously served as CEO of Amicus Therapeutics from 2022 until its acquisition by BioMarin in April 2026. He also held the roles of President and COO at Amicus. Campbell currently serves on the board of the Duke Margolis Health Policy Institute and previously served on the boards of Progenics Pharmaceuticals and ARYA Sciences Acquisition Corp III.
Travere has entered into an employment agreement with Campbell that includes a base salary of $1,000,000 and a target annual discretionary bonus of 85% of that salary. To offset relocation and other expenses, the company will provide a cash payment of $500,000, subject to repayment terms if he resigns without cause prior to the 24-month anniversary of his start date.
As part of his compensation package, Campbell will receive two initial equity awards with an aggregate value of approximately $16.5 million. These include a non-qualified stock option covering shares worth about $8.25 million and a time-based restricted stock unit award of the same value. Both awards will vest over four years. Additionally, Campbell will receive a performance-based restricted stock unit award valued at approximately $3.75 million in early 2027, contingent upon the achievement of future corporate and clinical milestones.
